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1. Introduction
Since the advent of knockout technologies using mouse embryonic stem cells in the late 1980s,
there has been an explosion of murine models to profile human diseases. The understanding
of the genetic contribution to these diseases has been further enhanced with the incorporation
of tissue-specific gene deletion strategies through the use of the Cre-lox and FLP-FRT site-
specific recombination systems. Autophagy, a crucial regulator of cell energy homeostasis, is
also a companion process to the ubiquitin-proteasome system to assist in the turnover of
proteins. Two distinct types of mouse models have been engineered to characterize autophagy.
The first type is based on the reporter model system to both detect and quantitate the in vivo
levels of autophagy in all tissues and organs. The second type is based on genomic modification
to perform global or tissue-specific gene deletions for generation of pathological disease
conditions. A wide array of human diseases and conditions have been shown to be intimately
linked to alterations in autophagy and include: 1) cancer, 2) heart disease, 3) neurodegenerative
diseases (e.g. Alzheimer’s and Parkinson’s disease), 4) aging, 5) lysosomal storage disorders,
6) infectious disease and immunity (e.g. Crohn’s disease), 7) muscle atrophy, 8) stroke, 9) type
2 diabetes, and 10) reproductive infertility. This article will address the role of autophagy in
human disease progression by reviewing the strengths and weaknesses of current murine
models, as well as discussing their utility as therapeutic models for disease prevention and
amelioration.
2. Transgenic models for autophagy detection
GFP-LC3. The best characterized and most widely used detection model is the GFP-LC3
transgenic mouse generated by Mizushima and colleagues [1]. This robustly expressing
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transgenic mouse, in which LC3 is driven by a constitutive CAG promoter, displays punctate
GFP fluorescence that corresponds to autophagosomes. With this transgenic model, quanti‐
tation of autophagosomes is feasible using a high resolution fluorescence microscopy. This
reporter has been crossed into many of the knockout and floxed autophagy models generated
in the field. For example, Atg5 -/- mice are autophagy deficient and Atg5 -/-; GFP-LC3 mice do
not exhibit the punctate fluorescence indicative of autophagosomes. Protocols for use are
widely available and published references are helpful, for detailed information see [2]. This
model is limited in that only autophagosome numbers, not autophagic flux, can be evaluated.
In basal conditions, lysosomal degradation clears the autophagosome and contents from the
cell, thus maintaining a “balance” of autophagosome formation and degradation. An accu‐
mulation of autophagosomes could either represent an increase in formation or a decrease in
fusion events. Ferreting out these differences is relevant for proper data interpretation
especially when using chemical autophagy inhibitors and inducers. Measuring autophagic
flux in vivo has been problematic to date and the field is in need of an appropriate reporter
model; currently, tandem fluorescent-tagged autophagy proteins are a valuable in vitro tool.
An increase in GFP puncta (denoting labeled autophagosomes) could indicate an increase in
autophagosome formation or a decrease in vesicular fusion with the lysosome. Due to its
chemical nature, GFP is quenched by the low pH of the autolysosome. Since red fluorescent
proteins are more pH stable, they have been utilized in assays designed to monitor autophagic
flux. The need for better detection mechanisms with regard to cardiac autophagy has led to
the generation of a double transgenic reporter. A cardiac muscle specific alpha myosin heavy
chain (αMyHC) promoter was used to drive expression of a mCherry-LC3 construct. These
mice were crossed with the GFP-LC3 model previously described to produce a double reporter
which allowed for the monitoring of autophagic flux; autophagosomes were identified by GFP
and mCherry co-localized puncta, while autolysosomes were tracked by mCherry-only puncta
[3]. Although this model is cardiac-specific, a similar strategy could be used to target other
tissues. Additionally, a dual labeled RFP-GFP-LC3 construct could be used to generate a
ubiquitous transgenic model to quantitate autophagic flux.
GFP-GABARAP. GFP-GABARAP transgenic mice were originally generated to address the
question of the role of GABARAP in podocytes. Since GABARAP was reported to be highly
expressed in podocytes, a pCAG-GFP-GABARAP transgenic mouse was produced in order to
examine subcellular localization in this specialized cell type. The expression level of GFP-
GABARAP is low, yet visible, ameliorating many of the potential effects of highly expressing
fluorescent proteins. In podocytes, GFP-GABARAP co-localized with p62 aggregates but not
LC3II. Although it was shown that GABARAP was not the preferred Atg8 ortholog for
conjugation in podocytes, this may prove to be a valuable reporter model in other tissues [4].
2.1. Cancer
As we will see as a common thread in many of the disease models featured in this chapter,
there is no consensus in the literature as to whether autophagy is protective or maladaptive.
The contribution of autophagy to cancer development is the most demonstrable example of
the Janus-like role of autophagy in disease pathogenesis, and perhaps the most thoroughly
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investigated. Autophagy is hypothecated to contribute to tumor progression through two
distinct mechanisms. Tumor growth is initially restricted when the centrally-located cells
undergo nutrient deprivation, hypoxia, and if prolonged, subsequently undergo necrosis. This
metabolic stress induces autophagy to maintain energy homeostasis and prevent necrosis until
neo-vascularization occurs. Angiogenesis is potentially able to restore a nutrient supply
throughout the tumor, promoting tumor survival and facilitating growth and metastasis.
Additionally, transformed cells that harbor defects in apoptosis and autophagy pathways
tumor cells undergo chronic necrosis, which foments vascularization of the necrotic area, thus
promoting tumorigenesis. Conversely, intact autophagy can be cytoprotective by eliminating
damaged or aged organelles and degrading aggregated or misfolded proteins, thus preventing
accumulation of tumorigenic and/or cytotoxic cellular inclusions.
These two scenarios are manifested in mouse models of autophagy disruption. When Beclin1
(Becn1) was heterozygously disrupted (Becn1+/-), these mice exhibited an increase in tumor
formation when compared to control littermates [5]. Disruptions in pro-autophagy genes Becn1
[6], UVRAG [7], and Bif-1[8] resulted in increased frequencies of lymphomas and mammary
neoplasias through an increase in genetic instability. TSC1/TSC2-deficient mice, which were
unable to effectively suppress mTOR, had reduced autophagy and a subsequent increase in
tumor occurrence [9, 10]. These models all bolster the stance that autophagy is tumor sup‐
pressive. The embryonic or neonatal lethality of many autophagy knockout models is prohib‐
itive for studying diseases, such as cancer, that are associated with age. Tissue-specific
knockout studies will provide more insights in elucidating gene-specific mechanisms for
tumor suppression. Evidence is forthcoming from cancer cell lines and primary tumor
profiling that autophagy is permissive for tumor growth and enhanced in primary tumors. In
a pancreatic cancer cell line (8988T cells), inhibition of autophagy by Atg5 siRNA resulted in
an inhibition of soft agar growth, a measure of tumorigenic potential [11]. In cell lines with
activated ras, a strong oncogene, autophagy was necessary for the quick growth and high
metabolic needs of tumor cells. These cancer cells were described as “addicted to autophagy,”
and the phenomenon was consistent amongst several Ras-activated cell lines (e.g. T14, H1299,
and CHT116). These data suggest that in quickly growing tumors, autophagy inhibition may
sensitize the cells to death thus enhancing available treatment options [12]. This study provides
primarily in vitro evidence of a role for autophagy induction in supporting tumor growth.
2.2. Heart disease
Coronary heart disease (CHD) is the leading cause of death of men and women in the United
States. CHD is caused by narrowing of the arteries that supply the heart. In mouse models a
standard treatment is to induce an ischemic event by surgically occluding one or more coronary
artery. This occlusion may be relieved at a later time (ischemia/reperfusion) or remain
(permanent occlusion). Interestingly, autophagy is induced in both ischemia/reperfusion (I/R)
events and permanent occlusion events but the outcomes are differential. During I/R events
autophagy is activated, however in Becn1+/- mice damage was reduced indicating that induc‐
tion of autophagy was maladaptive during reperfusion [13]. Conversely, autophagy appears
to be protective during permanent occlusion events. Long term ischemia causes relief of
Altering Autophagy: Mouse Models of Human Disease
http://dx.doi.org/10.5772/55258
123
mammalian target of rapamycin (mTOR) inhibition of autophagy, thus leading to autophagy
induction. In concordance with this, expression of a dominant negative mTOR regulator
resulted in a reduction of autophagy and subsequent increase in cardiac damage [14]. Two
recent mouse models of heart disease provide evidence supporting a protective role of
autophagy for the prevention of CHD [15]. Razani et al provided evidence that autophagy
prevented cholesterol crystal-induced inflammation that normally can lead to atherosclerosis.
Since high fat diets have been shown to inhibit autophagic flux, competent autophagic flux
may be necessary for the prevention of CHD [16].
In addition to CAD, congenital mutations and other pathological conditions (e.g. type 2
diabetes) my result in cardiomyopathies. In a recent study, Choi et al showed that in a
cardiomyopathy model resulting from a mutation in A-type lamins (A/C) resulted in active
mTOR in cardiomyocytes, which inhibited autophagy activation [17]. This lack of autophagy
activation was proposed to lead to an energy deficit and was detrimental to the survival of the
cardiomyocytes and resulted in disease progression. Further evidence of the protective role of
autophagy was obtained when autophagy was reactivated by the mTOR-inhibiting drug
rapamycin. In mice mutant for A-type lamins, rapamycin treatment attenuated the cardiomy‐
opathy phenotype. In another approach, a mouse model of diabetic cardiomyopathy, gener‐
ated by diet alteration to include a surplus of saturated fatty acids, has revealed that autophagy
was activated in response to pressure increase resultant from cardiac hypertrophy. Autophagy
induction was measured by increased Becn1 and LC3B mRNA, as well as increased GFP-LC3
puncta in the diabetic hypertrophy model. In this system, isolated cardiomyocytes that were
autophagy impaired did not develop hypertrophy, indicating that increased autophagy was
required for hypertrophy. Furthermore, isolated cardiomyocytes treated with myristate led to
an increase in Becn1 and Atg7 expression through a ceramide-dependent mechanism [18]. The
role of autophagy is complex and seems to be highly context specific with regard to heart
disease. It is apparent that the method by which autophagy is inhibited or induced and in
which type of model differentially dictates whether autophagy will result in a positive or
negative outcome.
2.3. Neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s disease)
Post-mitotic neurons rely heavily on basal autophagy to clear old, damaged organelles and
potentially harmful protein aggregates. Several neurodegenerative disorders result from
expansions of poly-glutamine or poly-alanine stretches, including Huntington’s disease,
Parkinson’s disease, spinocerebral ataxias, and fronto-temporal dementia. Mutant proteins
involved in these diseases have an increased propensity to aggregate and poison the cell;
accordingly, the disease progression is directly related to the amount of protein aggregates
formed in these patients. In normal physiology, neurons rely on both the proteasomal
degradation system and autophagy to maintain protein and energy homeostasis. It has been
shown that autophagy is used preferentially to remove large aggregated proteins or multi-
protein plaques. In a rat model of Machado-Joseph disease (spinocerebral ataxia type 3)
overexpression of Becn1 reduced both mutant ataxin-3 accumulation and ubiquitin-positive
inclusions [19]. It seems that autophagy is used as a compensatory mechanism to relieve the
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toxic effects of these mutant protein aggregates in the cell, serving a protective role. Neuronal-
specific conditional deletion of FIP200 (FIP200fl/fl; nestin-Cre) resulted in dystrophy (axonal
swelling), neurodegeneration, accumulation of polyubiquitinated proteins, damaged mito‐
chondria, and neuronal death. When compared to Atg5/Atg7 neuronal conditional deletion
models, the FIP200-/- phenotypes were more severe, present at an earlier age, and resulted in
premature death. Unique to the FIP200-/- conditional knockout mice is the development of
diffuse brain spongiosis, observed as early as 2 weeks of age, and associated with ubiquitin
positive inclusions, indicative of impaired clearance of cytotoxic proteins by autophagy [20].
Targeted deletions of either Atg5 or Atg7 resulted in the accumulation of polyubiquitinated
proteins and sensitized neurons to degeneration; supporting the hypothesis that autophagy is
neuroprotective [21, 22]. Purkinje cells (PC) reside within the gray matter at the interface
between the molecular and the granular layers of the cerebellar cortex and are important for
signal integration, balance, and motor coordination. PC-specific conditional deletion models
of Atg7 (Atg7fl/fl; pcp2-Cre) resulted in PC dystrophy and subsequent axon terminal degener‐
ation. PC degeneration was followed by PC death and behavioral changes in the mutant mice
[23]. In a similar experiment, deletion of Atg5 in PCs (Atg5 fl/fl; pcp2-Cre) also resulted in axonal
swelling and neurodegeneration [24]. Although both the nestin-Cre and pcp2-Cre have been
employed as useful tools to investigate the result of tissue-specific autophagy loss, one
important difference is that nestin-Cre is also expressed in some astrocyte populations as well
as other CNS structures, while pcp2-Cre is restricted to PCs. This difference may alter the
experimental designs, as nestin-Cre is more appropriate for diffuse CNS ablation studies and
pcp2-Cre is more Purkinje cell-specific.
2.4. Aging
Autophagy and its association with aging have been explored in two distinct contexts: 1) the
impact of autophagy on increasing lifespan or longevity, and 2) the role of autophagy in age-
related disease states. Longevity‑promoting regimens, including caloric restriction (CR) and
inhibition of TOR with rapamycin, resveratrol or the natural polyamine spermidine, have been
associated with autophagy induction [25]. CR can improve heart function through autophagy,
as long-term CR preserved cardiac contractile function with improved cardiomyocyte function
and lessened cardiac remodeling [26]. Rapamycin prolonged median and maximal lifespan of
both male and female mice when fed beginning at 600 days of age; this supplementation led
to a life span increase of 14% for females and 9% for males. In addition, rapamycin-treated
mice beginning at 270 days of age also increased survival in both males and females [27].
Lifelong administration of rapamycin extended the lifespan of female 129/Sv mice, as 22.9%
of rapamycin-treated mice survived the age of death of the last control mouse. Rapamycin also
inhibited age-related weight gain, decreased aging rate, and delayed spontaneous cancer
formation [28]. Although rapamycin and caloric restriction both increase the life span of mice,
they probably do not occur through similar mechanisms. Dietary restricted mice (40% food
restriction) and rapamycin-treated mice both exhibited increased levels of autophagy [29]. The
fat mass was similar between control and rapamycin-treated mice, but lower for the caloric
restricted mice. There were also striking differences in insulin sensitivity and expression of
cell cycle and sirtuin genes in mice fed rapamycin compared with dietary restriction. Spermi‐
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dine, a natural polyamine whose intracellular concentration declines during human aging,
extended the lifespan of yeast, flies and worms, and human immune cells. In addition,
spermidine administration potently inhibited oxidative stress in aging mice [30].
Basal autophagy helps to reduce the deleterious effects from oxidative stress, heat stress and
cytoplasmic protein aggregates. During the aging process, basal autophagy levels gradually
decline so that the cell is not equipped to deal with these stressors. Since many age-related
diseases correlate with a decline in basal autophagy, a targeted therapeutic strategy would be
to increase the levels of productive autophagy to reduce the severity of the disease. However,
it is important to keep in mind that a tight regulation of basal autophagy levels is important,
as too much autophagy could have a negative outcome. For example, in the Zmpste24-null
progeroid mice, which model the human laminopathy Hutchinson-Gilford Progeria Syn‐
drome (HPGS), there was an increase in autophagy instead of the anticipated reduction that
occurs during normal aging. Although autophagy levels were similar to those found associated
with caloric restriction and prolonged lifespan, in this instance autophagy was linked to having
a potential role in the premature aging phenotype. However, these mice also have several
metabolic alterations including changes in circulating hormones (e.g. leptin, insulin, adipo‐
nectin) and glucose levels that probably impact additional contributing cellular processes [31].
Progerin, the truncated form of lamin A protein, was found to co-localize with the autophagic
adapter protein p62 and the autophagy linked FYVE protein, ALFY [32]. Moreover, rapamycin
decreased progerin protein levels through autophagy induction, which rescued the progeria
phenotype in HGPS fibroblasts [33]. Rapamycin-induced autophagy has therapeutic implica‐
tions for other types of laminopathies as well. For example, Lmna-null (lamin A-deficient) mice
exhibited skeletal muscle dystrophy and cardiac hypertrophy; these pathologies were
improved through rapamycin administration [34]. An oxidative environment potentially plays
a crucial role in the aging process, as p62-/- mice exhibited accelerated aging phenotypes and
tissues displayed elevated oxidative stress due to defective mitochondrial electron transport
[35]. Likewise, Cisd2-null mice exhibited nerve and muscle degeneration and a premature
aging phenotype [36]. CISD2, the gene responsible for Wolfram syndrome 2 (WFS2), encodes
for a mitochondrial protein involved in mammalian life-span control. Although mitochondrial
degeneration was exacerbated with age with a concomitant elevation of autophagy, this
elevation was most likely due to a cellular response of mitophagy to clear damaged mito‐
chondria. In addition to induced-mutation mouse models, there have been several different
naturally occurring strains of senescence-prone (9 lines) and senescence-resistant (3 lines) mice
that have been developed since the 1970s at Kyoto University in Japan [37]. These mice have
been important to model aging, senile dementia, and Alzheimer’s disease. By 12 months of
age, the senescence accelerated mouse prone 8 (SAMP8) mice demonstrated a decline in
cognitive ability that corresponded to increased levels of ubiquitinated proteins and autopha‐
gic vacuoles (AV) in hippocampal neurons, and decreased expression levels of Becn1 [38]. In
contract, the senescence-resistant strain did not show an accumulation of these autophagic
vacuoles. In the future, it would be interesting to examine whether calorie restriction or
rapamycin administration could reduce the accumulation of ubiquitinated proteins and
improve learning and memory in the senescence-prone model.
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2.5. Lysosomal storage disorders
The group of degenerative disorders included in umbrella term lysosomal storage disorders
(LSDs) is a heterogeneous and emerging list of diseases that commonly present with an
inability to metabolize a normal cellular substrate. The metabolic defect may reside with the
ability of the lysosome to degrade the substrate, or a blockade of autophagic flux, most often
inhibiting fusion of the autophagosome and lysosome. A reduction in autophagic flux may
result in an increase in autophagosome like structures in the cytoplasm as well as uncharac‐
teristically large autophagosome like structures being formed. Consequently, failure to
eliminate/recycle the autophagosomal contents induces cellular stress and may result in death.
Pompe disease, the first LSD to be characterized, is caused by an inability to synthesize acid
α-glucosidase (GAA), a lysosomal enzyme needed to breakdown glycogen. Pompe mice (GAA
KO) phenocopied the human condition, and abnormal autophagosomal and autolysosomal
structures were seen intracellularly. When Pompe mice were crossed with Atg5/7 muscle-
specific conditional knockouts to inhibit autophagy, mice metabolized glycogen more
efficiently than the Pompe mice and had a more positive prognosis. In this model system,
autophagy was contributing to the pathology of the disease and inhibition of autophagy was
been shown to be a useful therapeutic intervention. A side effect of muscle-specific autophagy
inhibition, i.e. muscular atrophy, will be discussed in a later section.
Multiple sulfatase deficiency (MSD) is a disease where affected individuals have a reduction
in the activity of all sulfatases due to mutations in Sulfatase Modifying Factor 1 (SUMF1), an
enzyme responsible for post-translational modification of all sulfatases. A sumf1 knockout
mouse model shared characteristic manifestations of MSD including: skeletal abnormalities,
kyphosis, and growth retardation. Impaired autophagosome-lysosome fusion was implicated,
as a build-up of undigested material was detrimental to cellular homeostasis and led to death.
Though models have exhibited that MSD is accompanied by defective autophagic flux,
whether autophagy is protective or detrimental to the pathogenesis of the disease is unclear.
Mucopolysaccharidosis type VI (MPS VI) is caused by a specific sulfatase deficiency (N-acetylga‐
lactosamine-4-sulfate) and patients may be short in stature and suffer from joint stiffness and
destruction, cardiac valve abnormalities and corneal clouding. In a rat model of MPS VI, an
increased number of autophagic structures were identified by electron microscopy [39].
Niemann Pick type C disease is a metabolic disorder characterized by the accumulation of
lipids in late endosomes/lysosomes. The vast majority of cases are due to mutations in the
NPC1 gene. Npc1-/- mice had higher levels of autophagy proteins (LC3II) than controls, and
PCs were preferentially affected exhibiting an increase in autophagic vesicles by electron
microscopy. Npc-/- mice had the ability to form autophagosomes but were defective in auto‐
phagosome-lysosome fusion, which resulted in a functional autophagic block and inability to
metabolize cargo [40].
Mucolipidosis type IV disease (MLIV) is caused by mutations in the MCOLN1 gene which
encodes a lysosomal cation channel. Affected patients suffer from psychomotor delays and
multiple ophthalmic pathologies. The mcoln1-/- mouse model recapitulated most of the
symptoms observed in patients with the exception of corneal clouding. In mcoln1-/- brains,
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lysosomal inclusions were observed in several anatomical areas and cell types [41]. Neurons
had increased LC3-II expression and failed to clear LC3-II, once again indicating a functional
autophagic block that led to the pathogenesis [42].
2.6. Infectious disease and immunity (e.g. Crohn’s disease)
The innate immune system is the first line of defense against pathogens; it is evolutionarily
more ancient than the adaptive immune system and is deployed quickly and effectively despite
its lack of pathogen specificity or memory. Viruses, bacteria, and parasites can be eliminated
in an autophagic process involved in innate immunity defense termed ‘xenophagy.’ Invading
bacteria can generally be classified as vacuolar (e.g. Salmonella) or cytosolic (e.g. Listeria,
Shigella). Cytosolic bacteria can undergo ubiquitin-dependent and ubiquitin-independent
mechanisms for autophagosomal envelopment followed by translocation to lysosomes.
Vacuolar bacteria can be routed into autophagosomes, or in the instance of Mycobacteria,
autophagy proteins can resume the maturation of the vacuole and promoter fusion with the
lysosome. The main recognition receptors that link detection and autophagy induction include
the membrane TLRs (Toll-like receptors) and the cytoplasmic nucleotide-binding oligomeri‐
zation domains (NOD)-like receptors (NLRs). The receptors can recognize the lipopolysac‐
charides (LPS) and peptidylglycans of Gram-negative bacteria. Microbial interference with
autophagy can occur due to the adaptive nature of bacteria. For example, Shigella flexneri
secretes the protein lcsB, which prevented ATG5-induced autophagy at the bacterial surface.
Yersinia pseudotuberculosis resides within arrested autophagosomes in macrophages, since it
can inhibit the fusion process with lysosomes [43, 44].
The more complicated adaptive immune system also relies on autophagy in many capacities.
Studies inducing ablation of autophagy proteins have revealed an essential role for autophagy
in maintaining normal numbers of B cells, T cells and hematopoietic stem cell survival and
function. Atg5- and Atg7- deficient models have shown that autophagy was important for T
cell survival and maintenance of mitochondria. An increase in mitochondrial mass has been
correlated with T cell death in circulating T cells, indicating a potential mechanism of action
[45]. Thymic epithelial cells have a high rate of basal autophagy compared to other cell types.
During T cell selection thymic epithelial cells display decorations of “self” and “non-self”
antigens, aiding in this process autophagy is proposed to facilitate ligand (MHC-II molecule)
loading. When autophagy was depleted specifically in thymic epithelial cells, the mature T
cell repertoire was diminished due to alterations in positive and negative T cell selection
processes. Interestingly, severe colitis, patches of flakey skin, atrophy of uterus, absence of fat
pads and enlargement of lymph nodes were observed in many cases. Inflammation was
observed in the colon, uterus, lung and Harderian gland of recipient mice. These manifesta‐
tions are indicative of autoimmune diseases and this model provides a clear linkage between
autophagy and autoimmune/inflammatory diseases [46]. A B cell-specific ablation of Atg5 was
achieved by either a Cre-LoxP approach (Atg5fl/fl; CD19-Cre) or by repopulating irradiated mice
with progenitor cells derived from an Atg5-/- fetal liver. In these experiments, autophagy was
found to be essential for the survival of pre-B cells (after the pro-B cell to pre-B cell transition).
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Additionally, in peripheral circulation Atg5 was required to maintain normal numbers of B-1a
B cell populations but not B-2 B cells [47].
Genome wide association studies of Crohn’s Disease identified two autophagy associated
genes, Atg16L and IRGM. A naturally occurring insertion/deletion mutation was identified in
the 5’UTR (untranslated region) of IRGM (immunity-related GTPase family, M) which
disrupted a transcription factor binding site [48]. In another study, a SNP in the coding region
of IRGM was identified that affected a microRNA binding site [49]. These identified mutations
suggested that IRGM expression level changes were associated with Crohn’s disease in
humans. A mouse knockout model of Irgm1 (a.k.a. LRG-47) has been developed and does not
display any overt phenotype, including development of the immune system. However, when
challenged with infection, Irgm-/- mice were unable to control the replication of intracellular
pathogens [50]. Unfortunately, the Irgm1-knockout mice have not been investigated specifi‐
cally in the context of autophagy function in immunity to date. However in parallel with in
vitro data, IRGM1 has recently been shown to induce autophagy in a mouse model of stroke.
The promotion of autophagy, most likely at the level of LC3I to LC3II conversion, was generally
protective [51].
The relationship between Crohn’s disease and the autophagic process is more developed in
terms of investigating the Atg16L risk allele association by using two Atg16L gene trap models
and an intestinal epithelium-specific Atg5 knockout (Atg5fl/fl; villin-Cre). Both Atg16L gene trap
models (HM1 and HM2) result in a hypomorphic expression of Atg16L protein. Interestingly,
in the Atg16L mutants Paneth cells exhibited abnormal morphology including decreased
granule number and disorganization of granules. Researchers concluded that autophagy was
required to maintain fidelity of the Paneth cell granule exocytosis pathway. When challenged
with infection, the Atg16L hypomorphs performed similarly to controls. In Atg5fl/fl; villin-Cre
ileum, abnormal Paneth cells were identified which paralleled to those identified in the
ATG16L mutants. Human ileum samples from at risk patients were examined and also
exhibited abnormal Paneth cell morphology [52]. It is noteworthy at this point to mention that
genome wide association studies for ulcerative colitis did not identify either of these autophagy
genes, nor others. This suggests that Atg16L and IRMG are specific for the physiopathology of
Crohn’s disease, not inflammatory bowel diseases generally.
2.7. Muscle atrophy
Muscle atrophy is a symptom of a multitude of pathological states including but not limited
to fasting conditions, denervation, inactivity, cancer, cardiac failure, and diabetes. Autophagy
has been shown to be active in muscular atrophy and other myopathies however due to the
nature of the methods used it cannot be said with certainty whether autophagy is promoting
atrophy or is activated as a cytoprotective mechanism and coincides with pathology.
In a mouse tissue-specific mouse model generated to investigate the effect of superoxide
dismutase 1 (SOD1) ablation on skeletal muscle, it was found that mutants developed muscle
atrophy, reduction in contractile force and abnormal mitochondria. Significant upregulation
of the mitophagy (specific and selective form of autophagy wherein mitochondria are prefer‐
entially enveloped and degraded) gene Bnip3, as well as, autophagosome marker LC3 were
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detected by RT-PCR, most likely as a result of activation of transcription factor FoxO3. Oxidant
accumulation in SOD1-/- mice resulted in muscular atrophy through autophagy; this phenotype
was rescued by depletion of LC3 by siRNA knockdown suggesting that autophagy was the
driving pathway of atrophy. These findings imply that autophagy inhibition is a potential
therapeutic target for acute and chronic muscular atrophy [53].
Muscle-specific Atg7 conditional knockout mice were autophagy incompetent and morpho‐
logically diverged from wild type control littermates beginning at 40 days of age. Muscles of
the knockout mice exhibited degenerative changes and a decrease in myofiber size; these
abnormal changes were concurrent with the loss of muscle contractile force which further
decreased with increasing age. Even more telling may be the ultrastructural changes associated
with loss of autophagy in the muscles, abnormally large mitochondria, centrally located nuclei
and dilated sarcoplasmic reticulum all observed via electron microscopy [54].
As discussed previously, a muscle-specific Atg5 knockout mouse was generated and bred onto
a glycogen-degrading enzyme acid-alpha glucosidase knockout background (GAA-KO) to
interrogate the nature autophagic degradation of glycogen in the pathogenesis of Pompe
disease. This study provided additional evidence that autophagy functioned to prevent
muscular wasting. Muscle-specific GAA-/-; Atg5-/- mice developed progressive muscular
weakness and eventual paralysis beginning earlier (2-3 months of age) and progressing more
rapidly than autophagy-competent GAA KO mice. Ubiquitin-positive structures accumulated
in both GAA KO and GAA-/-; Atg5-/- mice with a differing distribution. In GAA KO myocytes,
autophagic vesicles built up in the cell and ubiquitin-positive structures associated with the
autophagosome. In GAA-/-; Atg5 -/- myocytes, ubiquitin-positive structures were distributed
throughout the cell and appeared to associate with lysosomes, though were not membrane
bound. These data indicated that the disruption of functional autophagy and accumulation of
toxic ubiquitin-positive structures promoted muscular myopathy [55].
2.8. Stroke
Cerebral ischemia is achieved in mice most often by surgical intervention and results in global,
restricted, or cerebral directed ischemia depending on the method selected. Furthermore in
some models ischemia is reversed, allowing reperfusion of the cerebral tissue. Autophagy is
induced by hypoxia/ischemia events; however it is unclear whether autophagy is protective
or maladaptive in stroke models. Responsibility of much of the dissenting opinions may be
attributed to the variety of techniques used to induce ischemia events, these have been
reviewed at length by Hossmann in [56]. Neonatal mice subjected to hypoxic/ischemic (H/I)
brain injury responded with a robust autophagic response in neurons and hippocampal
neuron death. Atg7-/- neonates, which are autophagy incompetent, were protected from
hippocampal neuron death when subjected to identical (H/I) brain injury as control mice,
indicating a neurotoxic role for autophagy induction [57]. Conversely, in when wild type mice
were subjected to H/I brain injury and reperfusion, damage was mitigated by intraperitoneal
injection of NAD+. NAD+ administration inhibited autophagy induction. In the NAD+ treated
group, a reduction of autophagy was correlated with a decrease in neuronal damage. To
further investigate this link, researchers subjected mice to H/I injury and treated them with 3-
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methyladenine (3-MA), an autophagy inhibitor, and an amelioration of neuronal damage was
observed. These data indicated that in adults, H/I brain injury followed by reperfusion
autophagy was maladaptive; furthermore, inhibition of autophagy at the time of reperfusion
was neuroprotective [58]. Moreover, in a rat ischemia model, inhibition of autophagy by Becn1-
directed shRNA or 3-MA treatment led to a reduction in damage and neuronal loss in the
ipsilateral thalamus. This study supported the hypothesis that autophagy induction increased
damage when activated following an ischemia/reperfusion event [59]. The variance amongst
the model systems could account for much of the disparity seen in outcomes. The age of the
individual, duration of ischemic event, and presence or absence of reperfusion is all potential
modulators autophagic response.
2.9. Type 2 diabetes
Type 2 diabetes (T2D) is a complex disease that manifests in tissues, especially adipose,
muscles, and liver, becoming resistant to insulin signaling and causing hyperglycemia.
Pancreatic β–cells initially respond by increasing their production of insulin, but prolonged
insulin resistance results in atresia of β–cells and a marked reduction in insulin production.
Due to the high metabolic demands placed on β–cells it follows that autophagy would be play
an important role in the pathophysiology of this chronic disease. In wild type C57BL/6 mice
β–cells, unlike most organs, autophagosomes are sparingly observed after a period of starva‐
tion. However, when mice were fed high fat diets for 12 weeks, autophagosomes were readily
observed. These results were confirmed in vitro by treating INS-1 β–cells with free fatty acid
(FFA), glucose, or tolbutamide. Cells treated with FFA had increased LC3II levels and
observable autophagosomes while cells treated with glucose or tolbutamide (a drug regularly
prescribed for T2D) did not show any significant change in LC3 conversion or autophagosome
formation. To further investigate the link between autophagy and β–cells, a β–cell specific
Atg7-/- mutant mice was generated (Atg7fl/fl; Rip-Cre). As early as 4 weeks, and degenerating in
an age-dependent manner, enlarged cells with pale staining cytoplasm were identified near
the periphery of Atg7fl/fl; Rip-Cre islets. Inclusion bodies were observed at a high frequency in
the enlarged cells the presence of inclusion bodies increased with age, and deformed mito‐
chondria were also observed in these enlarged cells. Resting blood glucose levels were higher
and insulin secretion was reduced in Atg7fl/fl; Rip-Cre mice when compared to control Atg7fl/fl
mice: these differences were amplified when control and Atg7fl/fl; Rip-Cre mice were fed high
fat diets [60]. In a related model, Marsh et al generated β–cells with a defective secretory
pathway in Rab3A-/- mice. Although increased intracellular insulin levels were expected, this
was not observed. Increased autophagy of the peptide hormone maintained the levels of
insulin and prevented accumulation of potentially toxic cellular substrates [61]. These
experiments together suggested that β–cells depended on autophagy to clear damaged
organelles and toxic intracellular protein aggregates.
2.10. Reproductive infertility
The role of  autophagy during folliculogenesis is  a comparatively new topic of study. In
rats,  LC3II  expression  was  characterized  in  follicles  of  varying  developmental  stages.
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Primordial  follicles  exhibited  only  weak expression,  but  antral  follicles  exhibited  robust
expression restricted to granulosa cells. Staining was not observed in the oocyte proper or
theca  cells  in  any stage  follicle  [62].  In  mice,  expression studies  also  indicate  a  role  for
autophagy  during  folliculogenesis.  An  expression  profile  of  Becn1  mRNA  revealed
significantly higher expression in primordial follicles than in other stages.  Immunohisto‐
chemistry for BECN1 confirmed this result and consistent staining of granulose cells, theca
cells  and oocyte cytoplasm was seen in all  follicular stages examined [63].  Interestingly,
when Becn1 or Atg7 is ablated specifically in the female germline (MMTV-CreA; Becn1fl/fl)
or globally (Atg7-/-),  fewer primordial follicles were present in the perinatal ovary. These
results indicated that autophagy may be vital for survival of the primordial follicle pool,
and be active during folliculogenesis and follicular atresia. In males it is well accepted that
autophagy is responsible for post fertilization paternal mitochondrial clearance to prevent
paternal mitochondrial DNA transmission; however, the role of autophagy during sperma‐
togenesis is a field in its nascence. It has been shown in Arabidopsis that Becn1 was essential
for pollen development [64]. Also, autophagy induction in stallion sperm, as measured by
LC3I to LC3II conversation, was important for the survival of sperm post ejaculation [65].
In  mice,  an  Atg5  sperm-specific  conditional  deletion  has  been  generated  and  males
developed  an  infertility  phenotype  at  approximately  15  weeks  due  to  accumulation  of
abnormal structures in the seminiferous tubules as well as abnormal sperm. Tsukamoto et
al. suggested that autophagy may be essential for normal spermiogenesis in mice in order
to effect cytoplasmic reduction [66].
In  conclusion,  a  variety  of  mouse  models  have  been  established  and  interrogated  to
understand the implications of autophagy in human disease. These genetic-based models
are primarily  either  reliant  upon:  1)  the generation of  an autophagy-defective mouse to
characterize a  given disease state,  or  2)  the characterization of  autophagy within a  pre-
established murine model. As this review has shown, conditional knockout models have
been extremely useful in disease profiling. The next wave of studies will invariably utilize
inducible-based  systems  for  conditional  knockouts,  genetic-based  rescue  experiments  of
disease models, or pharmaceutical-based modification of autophagy. A prevailing theme in
the field is that autophagy can either be beneficial or deleterious depending on the disease
and its progression state, a theme which must be addressed in designing and implement‐
ing appropriate treatment regimes.
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